Fig. 1
From: IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway
The effect of IMB0901 on MSTN promoter activity and MSTN signaling pathway. a The structural formula of IMB0901. b The cytotoxicity of IMB0901. MTT assay was used to detect the cell survival rate of HEK293T-MSTNP cells after 24-h treatment with IMB0901 at various concentrations. The values presented means ± SD from three experiments, each performed in triplicate. c The inhibition of IMB0901 on the MSTN promoter activity. Bright-Glo™ Luciferase Assay was applied to assess the luciferase activity of HEK293T-MSTNP cells after 24-h direct treatment with IMB0901 at various concentrations. The values were means ± SD from three experiments, each performed in triplicate. **P < 0.01 compared to the control group (0 μM). d The inhibition of IMB0901 on the MSTN positive feedback regulation. Bright-Glo™ Luciferase Assay was applied to assess the luciferase activity of MSTN-activated HEK293T-MSTNP cells after 24-h treatment with IMB0901 at various concentrations. The data presented means ± SD from three experiments, each performed in triplicate. *P < 0.05 compared to the control group, ##P < 0.01 compared to the MSTN group. e The inhibition of IMB0901 on the MSTN signaling pathway. Bright-Glo™ Luciferase Assay was used to detect the luciferase activity of MSTN-activated HEK293-SBE cells after 24-h treatment with IMB0901 at various concentrations. The values were means ± SD from three different experiments, each performed in triplicate. **P < 0.01 compared to the control group, ##P < 0.01 compared to the MSTN group